A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

Solid Tumor Clinical Trial

Official title:

Phase 1, FIH, Open-label, Nonrandomized, Multicenter Study of JZP815 in Participants With Advanced or Metastatic Solid Tumors Harboring Alterations in the MAPK Pathway

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05557045
• Other study ID #: JZP815-101
• Status: Recruiting
• Phase: Phase 1
• Start date: October 10, 2022
• Est. completion date: April 1, 2028

Study information

• Verified date: April 2024
• Source: Jazz Pharmaceuticals
• Contact: Clinical Trial Disclosure & Transparency
• Phone: 215-832-3750
• Email: ClinicalTrialDisclosure[@]JazzPharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.

Description:

This first-in-human study will consist of two parts: Part A and Part B. Part A will characterize the safety and tolerability of JZP815, assess pharmacokinetics (PK) profile, and determine a recommended phase 2 dose (RP2D) to be further investigated in the Expansion phase (Part B). Part B will further investigate the RP2D determined in Part A, and assess antitumor activity in various subsets of disease (based on mutation and/or tumor type) in which the mechanism of action of JZP815 is applicable.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 332
• Est. completion date: April 1, 2028
• Est. primary completion date: April 1, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participant must be = 18 years of age, at the time of signing the informed consent
• Participants who have histological or cytological diagnosis of an advanced or metastatic solid tumor carrying a documented, clinically significant, MAPK pathway alteration
• Participants must have exhausted all available standard of care therapies, or in the opinion of the investigator would be unlikely to tolerate or derive clinically meaningful benefit from available standard of care therapy
• Performance status (ECOG) of 0 or 1, measured within 72 hours before start of treatment
• Must have measurable disease by RECIST v1.1
• Tumor must be safely amenable to core needle or excisional biopsy (applies only to participants enrolled in Pre-Expansion cohorts)
• Adequate organ function
• Expected life expectancy of at least 12 weeks
• For each arm in Part B (Expansion), participant must be diagnosed with the tumor type(s) carrying the mutation(s) specified and meet protocol specified requirements for prior therapy
• Male participants must agree to refrain from donating sperm plus either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent or must agree to use contraception
• Female participants are eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: is a women of nonchildbearing potential (WONCBP) or is a women of childbearing potential (WOCBP) and using a contraceptive method that is highly effective during the study intervention period and for at least 3 months after the last dose of study intervention and agrees not to donate eggs
• A WOCBP must have a negative highly sensitive pregnancy test (urine or serum) within 3 days before the first dose of study intervention
• Capable of giving signed informed consent

Exclusion Criteria:

• Known uncontrolled brain metastases. Stable brain metastases either treated or being treated with a stable dose of steroids/anticonvulsants, with no dose change in the previous 4 weeks, are permitted
• Active fungal, bacterial and/or known viral infection including HIV or Hepatitis A, B, C
• Concomitant malignancies or previous malignancies with less than 2 years disease-free interval at the time of enrollment, with the exception of non-metastatic, non-melanomatous skin cancers, carcinoma in-situ, melanoma in-situ, prostate cancer with undetectable PSA that are adequately treated
• Has clinically significant (ie, active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (> New York Heart Association Classification Class II), QTc = 470 msec, or serious cardiac arrhythmia requiring medication
• Uncontrolled or severe intercurrent medical condition
• Gastrointestinal condition that could impair absorption of study intervention or inability to ingest study intervention
• In the judgement of the investigator, any important medical illness or abnormal laboratory finding that would increase the risk of participating in this study
• Received any cancer directed therapy (chemotherapy, hormonal therapy, biologic, etc.) within 28 days or 5 half-lives (whichever is shorter) of starting study intervention. Participants who have received radiotherapy must have recovered from acute toxicities associated with treatment.
• Use of any products or medicines known to be strong or moderate inducers or inhibitors of CYP3A4, which cannot be discontinued at least 4 weeks or 5 half-lives (whichever is shorter) before starting study intervention, or planned use at any time during the study
• Use of proton pump inhibitors and histamine-2 receptor antagonists, which cannot be discontinued at least 2 weeks before first dose, or planned use at any time during the study
• Concurrent therapy with any other investigational agent

Related Conditions & MeSH terms

• Advanced Cancer
• Metastatic Cancer
• Neoplasm Metastasis
• Solid Tumor

Intervention

Drug:
• JZP815
JZP815 will be administered as oral capsules to participants BID approximately 12 hours apart, in the morning and in the evening. QD dosing may also be investigated, if supported by PK data.

Locations

Country	Name	City	State
United States	SCRI HealthOne	Denver	Colorado
United States	Tennessee Oncology - Nashville	Nashville	Tennessee
United States	Icahn School of Medicine at Mount Sinai	New York	New York
United States	Oklahoma University	Oklahoma City	Oklahoma
United States	Florida Cancer Specialists - Lake Nona	Orlando	Florida
United States	Sidney Kimmel Cancer Center	Philadelphia	Pennsylvania
United States	Florida Cancer Specialists - Sarasota	Sarasota	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Jazz Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Dose-Limiting Toxicities (Part A)		Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary	Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events (Part A and B)		Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary	Change From Baseline in Hemoglobin (Part A and B)		Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary	Change From Baseline in Absolute Neutrophil Count (Part A and B)		Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary	Change From Baseline in Platelets (Part A and B)		Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary	Change From Baseline in Hematocrit (Part A and B)		Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary	Change From Baseline in Aspartate Aminotransferase (Part A and B)		Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary	Change From Baseline in Alanine Aminotransferase (Part A and B)		Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary	Change From Baseline in Creatinine (Part A and B)		Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary	Change From Baseline in Total Bilirubin (Part A and B)		Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary	Change From Baseline in Heart Rate (Part A and B)		Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary	Change From Baseline in Blood Pressure (Part A and B)		Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary	Number of Participants With Dose Interruptions and Reductions (Part A and B)		Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary	Objective Response Rate (as Defined by RECIST v1.1) (Part B)		Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Primary	Duration of Response (Part B)		Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Secondary	Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) Levels of JZP815 and its Metabolites (Part A)		Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose
Secondary	Pharmacokinetic Parameter Time to Maximum Plasma Concentration (Tmax) of JZP815 and its Metabolites (Part A)		Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose
Secondary	Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) of JZP815 and its Metabolites (Part A)	AUC from time 0 to infinity (AUCinf) and AUC during a dosing interval (AUCtau) will be assessed.	Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose
Secondary	Pharmacokinetic Parameter Apparent Terminal Elimination Half-life (t1/2) of JZP815 and its Metabolites (Part A)		Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose
Secondary	Pharmacokinetic Parameter Clearance (CL/F) of JZP815 and its Metabolites (Part A)		Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose
Secondary	Pharmacokinetic Parameter Accumulation Ratio of JZP815 and its Metabolites (Part A)		Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose
Secondary	Pharmacokinetic Parameter Apparent Volume of Distribution During Terminal Phase (Vz/F) of JZP815 and its Metabolites (Part A)		Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose
Secondary	Pharmacokinetic Parameter Metabolite to Parent Ratio of JZP815 and its Metabolites (Part A)		Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose
Secondary	Dose Proportionality of JZP815 and its Metabolites (Part A)		Dose levels 1 and 2, Cycle 1 Days 1 and 15:predose and 0.25,0.5,1,2,3,4,6, 8 hours (hr) postdose; 24, 48 and 72 hr postdose relative to first dose given on Cycle 1 Day 1; Other patients, Cycle 1 Days 1 and 15: predose and 0.25,0.5,1,2,3,4,6,8 hr postdose
Secondary	Objective Response Rate (as Defined by RECIST v1.1) (Part A)		Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Secondary	Progression-free Survival (Part B)		Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention
Secondary	Overall Survival (Part B)		Baseline until death, withdrawal of consent, or lost to follow-up, up to 18 months after last participant starts study intervention